New Assay to Test Target Compounds for Anti-Obesity Therapeutics
State College, PA (September 18, 2014) – INDIGO Biosciences, a leading provider of nuclear receptor products and services announced today that it has released a new Human Estrogen-related Orphan Receptor Gamma (NR3B3; ERRγ) Assay System. Three different assay kits are available.
ERRg is naturally expressed in the central nervous system, and at lower relative levels in a variety of other tissue types, including kidney, pancreas, skeletal muscle, heart and prostate. ERRg is a potential target for anti-obesity therapeutics. Cross-talk between ERRg and the estrogen receptor (ERa) has also been demonstrated. In addition, functional interactions between these two nuclear receptors may impact endocrine signaling involved in the progression of breast and prostate cancers. ERRg presents a potentially important therapeutic target for combating these diseases.
“This nuclear receptor assay system utilizes proprietary mammalian reporter cells to provide high-level expression of a hybrid form of the Human Estrogen-Related Receptor Gamma, said Dr. Jack Vanden Heuvel, Chief Scientific Officer. “The cells also incorporate the luciferase reporter gene, which provides an extremely sensitive measure of changes in ERRg activity resulting from exposure to the user’s test compounds.”
INDIGO’s Human ERRγ Assay kits are an all-inclusive, single use assay system. In addition to ERRγ Reporter Cells, kits provide optimized media for use during cell culture and in diluting user test samples, a reference inverse-agonist, Luciferase Detection Reagent, and a cell culture-ready assay plate. ERRγ Reporter Assay kits are available in 96-well, 3×32-well, and 384-well assay formats.
INDIGO offers a comprehensive menu of nuclear receptor screening products and services, as well as non-human nuclear receptor assays, functional assays and custom assay development. All of INDIGO’s reporter cells are prepared using their proprietary CryoMite™ process, which provides long-term cryo-preservation of cells for shipping and storage, allowing on-demand use of the products in their customers’ labs.
About INDIGO Biosciences
INDIGO Biosciences, Inc. was founded in State College, Pennsylvania in 2005. As a privately held biosciences company, INDIGO offers both products and services focused on nuclear receptors. INDIGO provides high-quality, confidential screening services and assay kits for the pharmaceutical, biotechnology, agri-business, nutriceutical industries, government research agencies, and academic researchers. For more information visit: www.indigobiosciences.com